Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 2/20 | 0.35 |
| ▸ | FURIN | P09958 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SDCBP | O00560 | 2/20 | 0.34 |
| ▸ | SDC2 | P34741 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30920966 | 0.85 | NOD1 (0.52) | NOD1GLO1BMP1PTGS1GSTK1 | |
| SCHEMBL30832635 | 0.85 | NOD1 (0.49) | NOD1GLO1BMP1PTGS1GSTK1 | |
| SCHEMBL31039964 | 0.84 | BACE1 (0.46) | GLO1PTGS1GSTK1DPP4DPP8 | |
| SCHEMBL30558188 | 0.84 | DPP4 (0.48) | NOD1GLO1PTGS1GSTK1DPP4 | |
| SCHEMBL3358182 | 0.83 | GLO1 (0.48) | NOD1GLO1BMP1PTGS1GSTK1 | |
| SCHEMBL29349612 | 0.82 | ALDH1A1 (0.42) | SDCBPSDC2ALDH1A1EPHX2NPSR1 | |
| SCHEMBL11841346 | 0.82 | OPRM1 (0.46) | FURIN | |
| SCHEMBL11832854 | 0.82 | OPRM1 (0.46) | FURIN | |
| SCHEMBL7614754 | 0.81 | NOD1 (0.52) | NOD1GLO1BMP1PTGS1GSTK1 | |
| SCHEMBL7614745 | 0.81 | NOD1 (0.52) | NOD1GLO1BMP1PTGS1GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| EP-4486366-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2025-01-08 | — | — | EP | claimed |
| CN-119156221-A | Improved oral pharmaceutical formulations of therapeutic peptides and proteins | 西普鲁梅有限公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2023166179-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2023-09-07 | — | — | WO | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | disclosed |
| US-20250295587-A1 | COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF | SAIL BIOMEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20220152139-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-05-19 | — | — | US | disclosed |
| US-11324736-B2 | Method of Treating Focal Segmental Glomerulosclerosis | CHEMOCENTRYX, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2022069576-A1 | AUTOPHAGY-INHIBITING PEPTIDE AND ORGANIC ACID SALT THEREOF ADDRESSING ISSUES OF VASCULAR PERMEABILITY | BIOTEMPT B.V. (NL) | 2022-04-07 | — | — | WO | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20220024991-A1 | ENGINEERED FLAGELLIN-DERIVED COMPOSITIONS AND USES | GENOME PROT INC (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | NOD1 1617/4885GLO1 3225/4885BMP1 249/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | NOD1 872/4885GLO1 207/4885BMP1 877/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | NOD1 305/4885GLO1 947/4885BMP1 123/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | NOD1 218/4885GLO1 923/4885BMP1 1447/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | NOD1 1861/4885GLO1 2874/4885BMP1 135/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | NOD1 698/4885GLO1 3315/4885BMP1 3346/4885 |
| US-11324736-B2 | Method of Treating Focal Segmental Glomerulosclerosis | SLC5A1, PTGFR, HPGDS | NOD1 2509/4885GLO1 3884/4885BMP1 352/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | NOD1 679/4885GLO1 317/4885BMP1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.